146 related articles for article (PubMed ID: 2343042)
1. Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models.
Tani S; Okabayashi Y; Nakamura T; Fujii M; Itoh H; Otsuki M
Pancreas; 1990 May; 5(3):284-90. PubMed ID: 2343042
[TBL] [Abstract][Full Text] [Related]
2. CCK administration after CCK receptor blockade accelerates recovery from cerulein-induced acute pancreatitis in rats.
Nakano S; Kihara Y; Otsuki M
Pancreas; 1998 Mar; 16(2):169-75. PubMed ID: 9510141
[TBL] [Abstract][Full Text] [Related]
3. Effect of a new cholecystokinin receptor antagonist CR 1392 on caerulein-induced acute pancreatitis in rats.
Otsuki M; Tani S; Okabayshi Y; Nakamura T; Fujii M; Fujisawa T; Baba S; Itoh H
Pancreas; 1989; 4(2):237-43. PubMed ID: 2474165
[TBL] [Abstract][Full Text] [Related]
4. Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis.
Nakano S; Tachibana I; Otsuki M
Pancreas; 1995 Apr; 10(3):287-94. PubMed ID: 7542770
[TBL] [Abstract][Full Text] [Related]
5. Fasting prevents acute pancreatitis induced by cerulein in rats.
Otsuki M; Tani S; Okabayashi Y; Fujii M; Nakamura T; Fujisawa T; Koide M; Itoh H
Dig Dis Sci; 1990 Jul; 35(7):840-8. PubMed ID: 2364838
[TBL] [Abstract][Full Text] [Related]
6. Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate.
Kimura K; Tominaga K; Fujii M; Saito T; Kasai H
Arzneimittelforschung; 1998 Jan; 48(1):65-9. PubMed ID: 9522035
[TBL] [Abstract][Full Text] [Related]
7. Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop.
Tani S; Itoh H; Koide M; Okabayashi Y; Otsuki M
Pancreas; 1993 Jan; 8(1):109-15. PubMed ID: 7678322
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of CR 1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and mice.
Makovec F; Bani M; Cereda R; Chistè R; Revel L; Rovati LC; Setnikar I; Rovati LA
Peptides; 1986; 7(6):1159-64. PubMed ID: 3104890
[TBL] [Abstract][Full Text] [Related]
9. Experimental acute pancreatitis induced by excessive doses of caerulein in rats; protective and therapeutic effects of trypsin inhibitor urinastatin and CCK receptor antagonist CR1392.
Tani S
Kobe J Med Sci; 1988 Apr; 34(2):93-112. PubMed ID: 3216603
[No Abstract] [Full Text] [Related]
10. Asperlicin, a nonpeptidal cholecystokinin receptor antagonist, attenuates sodium taurocholate-induced acute pancreatitis in rats.
Wisner JR; Renner IG
Pancreas; 1988; 3(2):174-9. PubMed ID: 2453874
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of loxiglumide on experimental acute pancreatitis using various models.
Satake K; Kimura K; Saito T
Digestion; 1999; 60 Suppl 1():64-8. PubMed ID: 10026435
[TBL] [Abstract][Full Text] [Related]
12. Treatment with cholecystokinin receptor antagonist loxiglumide enhances insulin response to intravenous glucose stimulation in postpancreatitic rats.
Otsuki M; Nakano S; Tachibana I
Regul Pept; 1994 Jul; 52(2):85-95. PubMed ID: 7972939
[TBL] [Abstract][Full Text] [Related]
13. Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis.
Taniguchi H; Yomota E; Kume E; Shikano T; Endo T; Nagasaki M
Jpn J Pharmacol; 1997 Feb; 73(2):105-12. PubMed ID: 9074944
[TBL] [Abstract][Full Text] [Related]
14. Effects of MCI-727 on pancreatic exocrine secretion and acute pancreatitis in two experimental rat models.
Tachibana I; Watanabe N; Shirohara H; Akiyama T; Nakano S; Otsuki M
Pancreas; 1996 Mar; 12(2):165-72. PubMed ID: 8720664
[TBL] [Abstract][Full Text] [Related]
15. Influence of the CCK-antagonist loxiglumide on bile-induced experimental pancreatitis.
Leonhardt U; Seidensticker F; Fussek M; Stöckmann F; Creutzfeldt W
Int J Pancreatol; 1991 Sep; 10(1):73-80. PubMed ID: 1757732
[TBL] [Abstract][Full Text] [Related]
16. Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas.
Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S
Dig Dis Sci; 1989 Jun; 34(6):857-64. PubMed ID: 2470557
[TBL] [Abstract][Full Text] [Related]
17. Loxiglumide protects against experimental pancreatitis.
Setnikar I; Bani M; Cereda R; Chisté R; Makovec F; Pacini MA; Revel L
Arzneimittelforschung; 1987 Oct; 37(10):1172-4. PubMed ID: 3435590
[TBL] [Abstract][Full Text] [Related]
18. Caerulein-induced acute necrotizing pancreatitis in mice: protective effects of proglumide, benzotript, and secretin.
Niederau C; Ferrell LD; Grendell JH
Gastroenterology; 1985 May; 88(5 Pt 1):1192-204. PubMed ID: 2984080
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan.
Shiratori K; Takeuchi T; Satake K; Matsuno S;
Pancreas; 2002 Jul; 25(1):e1-5. PubMed ID: 12131781
[TBL] [Abstract][Full Text] [Related]
20. Effects of tetraprenylacetone on pancreatic exocrine secretion and acute pancreatitis in two experimental models in rats.
Tachibana I; Watanabe N; Shirohara H; Akiyama T; Nanano S; Otsuki M
Int J Pancreatol; 1995 Apr; 17(2):147-54. PubMed ID: 7542690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
